Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavrilimumab - Kiniksa Pharmaceuticals

Drug Profile

Mavrilimumab - Kiniksa Pharmaceuticals

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer Kiniksa Pharmaceuticals; MedImmune
  • Class Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Granulocyte-macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Giant cell arteritis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2019 Pharmacodynamics data from a preclinical trial in Giant cell arteritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 14 Mar 2019 Phase-II clinical trials in Giant cell arteritis (In the elderly, In adults) in Belgium, Italy, Netherlands, Serbia, Slovenia, United Kingdom, Germany, Croatia and USA (SC) (NCT03827018) (EudraCT2018-001003-36)
  • 21 Dec 2018 Phase-II clinical trials in Giant cell arteritis (In the elderly, In adults) in New Zealand, Australia, Spain (SC) (NCT03827018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top